Funding Opportunities

NIH Funding Opportunities

Notice of NIA Participation in PAR-17-486: "Short-term Mentored Career Enhancement Awards for Mid-Career Investigators to Integrate Basic Behavioral and Social Sciences (K18 Clinical Trial Required)"
Notice NOT-AG-17-027 from the NIH Guide for Grants and Contracts
Mon, 11 Dec 2017 12:28:15 EST

Notice of NIAMS' Participation in PA-18-398 "NIH Pathway to Independence Award (Parent K99/R00 - Independent Clinical Trial Not Allowed"
Notice NOT-AR-18-012 from the NIH Guide for Grants and Contracts
Wed, 13 Dec 2017 02:26:47 EST

Notice of Clarification on Award Project Period for PAR-17-003 "Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (R01)"
Notice NOT-CA-18-026 from the NIH Guide for Grants and Contracts
Wed, 13 Dec 2017 02:23:37 EST

Notice of Intent to Publish a Funding Opportunity Announcement for Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (R01 )
Notice NOT-DA-17-064 from the NIH Guide for Grants and Contracts
Mon, 11 Dec 2017 10:46:00 EST

NIBIB Notice to Clarify the Types of Clinical Trials NIBIB Will Support Under PAR-18-205, NIBIB Biomedical Technology Resource Centers (P41 Clinical Trial Optional)
Notice NOT-EB-18-001 from the NIH Guide for Grants and Contracts
Wed, 13 Dec 2017 02:08:48 EST

Notice to Clarify the Types of Clinical Trials NIBIB Will Support Under PAR-18-206 Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional)
Notice NOT-EB-18-002 from the NIH Guide for Grants and Contracts
Thu, 14 Dec 2017 09:35:53 EST

Notice of Participation of the National Institute of Environmental Health Sciences in PA-18-370 "Independent Scientist Award (Parent K02 - Independent Clinical Trial Required)"
Notice NOT-ES-18-002 from the NIH Guide for Grants and Contracts
Wed, 13 Dec 2017 09:51:48 EST

Notice of Participation of the National Institute of Environmental Health Sciences in PA-18-372 " Mentored Clinical Scientist Research Career Development Award (Parent K08 - Independent Clinical Trial Required)"
Notice NOT-ES-18-003 from the NIH Guide for Grants and Contracts
Thu, 14 Dec 2017 11:36:28 EST

Notice of Participation of the National Institute of Environmental Health Sciences in PA-18-374 "Mentored Patient-Oriented Research Career Development Award (Parent K23 - Clinical Trial Required)"
Notice NOT-ES-18-004 from the NIH Guide for Grants and Contracts
Thu, 14 Dec 2017 11:31:04 EST

Notice of Participation of the National Institute of Environmental Health Sciences in PA-18-393 "Midcareer Investigator Award in Patient-Oriented Research (Parent K24 Clinical Trial Required)"
Notice NOT-ES-18-005 from the NIH Guide for Grants and Contracts
Thu, 14 Dec 2017 09:43:12 EST

Notice of Cancellation of the October 2018 Receipt Date for RFA-FD-16-043
Notice NOT-FD-18-006 from the NIH Guide for Grants and Contracts
Wed, 13 Dec 2017 11:35:16 EST

Reminder of Required Letter of Support for PAR-17-094 "Maximizing Investigators Research Award (R35)"
Notice NOT-GM-18-011 from the NIH Guide for Grants and Contracts
Mon, 11 Dec 2017 10:53:06 EST

Notice of Change in Eligibility for PAR-17-094 "Maximizing Investigators Research Award (R35)"
Notice NOT-GM-18-012 from the NIH Guide for Grants and Contracts
Mon, 11 Dec 2017 10:35:19 EST

NHLBI Announces Participation in PA-18-404 "Ruth L. Kirschstein National Research Service Award (NRSA) Short-Term Research Training Grant (Parent T35)"
Notice NOT-HL-17-560 from the NIH Guide for Grants and Contracts
Mon, 11 Dec 2017 02:15:07 EST

Collaborative Research in Computational Neuroscience (CRCNS) NSFInnovative Approaches to Science and Engineering Research on Brain Function
Notice NOT-MH-18-012 from the NIH Guide for Grants and Contracts
Mon, 11 Dec 2017 11:01:40 EST

Notice of NINDS' Participation in PA-18-403 "Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grant (Parent T32)"
Notice NOT-NS-18-022 from the NIH Guide for Grants and Contracts
Thu, 14 Dec 2017 11:51:26 EST

Notice of National Institute of Neurological Disorders and Stroke (NINDS) and National Institute on Drug Abuse (NIDA) Interest in Blueprint Neurotherapeutic Network Applications Directed at Small Molecule Non-Addictive Pain Therapies
Notice NOT-NS-18-027 from the NIH Guide for Grants and Contracts
Wed, 13 Dec 2017 11:41:48 EST

Notice of Clarification of NINDS Statement of interest for "Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional)"
Notice NOT-NS-18-028 from the NIH Guide for Grants and Contracts
Thu, 14 Dec 2017 08:58:10 EST

Additional Short-Term Administrative Relief to Institutions Impacted by Hurricanes Harvey, Irma, and Maria
Notice NOT-OD-18-114 from the NIH Guide for Grants and Contracts
Tue, 12 Dec 2017 10:55:33 EST

Reminder: Annual Reports to the Office of Laboratory Animal Welfare due January 31, 2018
Notice NOT-OD-18-117 from the NIH Guide for Grants and Contracts
Thu, 14 Dec 2017 08:42:49 EST

Request for Information on the Office of Disease Prevention Strategic Plan for Fiscal Years (FY) 20192023
Notice NOT-OD-18-118 from the NIH Guide for Grants and Contracts
Mon, 11 Dec 2017 11:09:37 EST

Interaction of HIV Infection and Alcohol Abuse on Central Nervous System Morbidity Limited Competition (U01 Clinical Trial Not Allowed)
Funding Opportunity RFA-AA-18-008 from the NIH Guide for Grants and Contracts. The National Institute on Alcohol Abuse and Alcoholism (NIAAA) invites a limited competing renewal of a U01 project to evaluate the cumulative and progressive effects on brain structure and cognitive/behavioral function of combined HIV infection and alcohol abuse. This project has recruited and longitudinally tracked a large cohort of individuals with HIV infection, or alcohol abuse, or the comorbid condition. As members of this cohort are growing older and living well longer due to antiretroviral medications, this project is well suited to address several questions of current interest in the HIV-AIDS research community. These questions include the effects of coinfection with the Hepatitis C virus, the involvement of peripheral neuropathy as a factor in frailty, potential neurotoxic effects of antiretroviral medications, and interactive effects with advancing age on sensory and motor functioning.
Wed, 13 Dec 2017 09:13:43 EST

Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3) (Clinical Trials Optional)
Funding Opportunity RFA-DA-19-002 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement is to support the discovery and development of medications to prevent and treat opioid use disorders (OUD) and overdose. The UG3/UH3 Phase Innovation Awards Cooperative Agreement involves 2 phases. The UG3 is to support a project with specific milestones to be accomplished by the end of the 2-year period. The UH3 is to provide funding for 3 years to a project that successfully completed the milestones set in the UG3. UG3 projects that have met their milestones will be administratively considered by NIDA and prioritized for transition to the UH3 phase. Investigators responding to this FOA must address both UG3 and UH3 phases. Application may include preclinical or clinical research studies that will have high impact and quickly yield the necessary results to advance closer to FDA approval medications that are safe and effective to prevent and treat OUDs and overdose. The compounds to be evaluated can be small molecules or biologics. They can be tested in pre-clinical models and/or for the clinical manifestations of OUDs such as withdrawal, craving, relapse, or overdose. Applications may focus on the development of new chemical entities, new formulations of marketed medications available for other indications, or combinations of medications that hold promise for the treatment of OUDs and overdose. Through this FOA, NIDA seeks to fast-track the discovery and development of medications to prevent and treat OUDs or opioid overdose and to advance them in the FDA's drug development approval pipeline.
Thu, 14 Dec 2017 11:20:34 EST

NIDCR Dental Specialty and PhD Program (DSPP)(K12-Clinical Trials Not Allowed)
Funding Opportunity RFA-DE-18-012 from the NIH Guide for Grants and Contracts. The Dental Specialty and PhD Program (DSPP) FOA encourages applications for institutional research career development (K12) programs from organizations that propose to develop outstanding clinician scientists through an integrated program of advanced clinical training in a recognized dental specialty and supervised research training leading to a PhD in biomedical or behavioral science, or in another field applicable to dental, oral and craniofacial research. The program should accelerate the process of early career dentist scientists in achieving competencies in both clinical and research areas and facilitate the transition to an independent and productive research career dedicated to improving dental, oral and craniofacial health.
Mon, 11 Dec 2017 01:49:39 EST

Microphysiological Systems (MPS) for Modeling Diabetes (UG3/UH3 Clinical Trial Not Allowed)
Funding Opportunity RFA-DK-17-035 from the NIH Guide for Grants and Contracts. NIDDK requests applications to join a new research consortium "Microphysiological Systems (MPS) for Modeling Diabetes (MPS-MOD)". NIDDK will support the development and validation of human tissue chips that closely mimic the normal physiology of key metabolic tissues, including the pancreatic islet, liver, skeletal muscle, and white adipose tissue (WAT). Experimental designs for the MPS-MOD platforms should incorporate strategies to measure pathophysiological changes associated with metabolic disease, including the impact of immune cells on metabolic dysfunction. Once developed, these multi-dimensional MPS-MOD platforms will serve as the foundation for NIDDK's advanced strategy to identify new and novel therapeutics for diabetes. The utility and validity of model systems developed under this initiative will be measured, in part, through the ability of known diabetes therapeutic agents and biomarkers to influence biology of the system, using best practices and rigorous study design. The need for high-quality, well-characterized isogenic/patient derived iPSC (induced pluripotent stem cell) lines and standardized differentiation procedures is a critical step in turning disease-specific lines into tools for discovery. In the future, iPSC-based human tissue chips could play a central role in drug development, testing, screening, drug repurposing and toxicity testing. Eventually, collections of iPSCs that capture the heterogeneity of T2D could be used to conduct "clinical trials in a dish", to discover biomarkers of response and to develop personalized treatments. An essential feature of this program will be a multidisciplinary approach that brings together basic science experts and physician scientists in stem cell biology, bioengineering, computational biology, pharmacology, liver biology, islet biology, adipose biology, metabolism and diabetes.
Mon, 11 Dec 2017 01:37:28 EST

Non-Invasive Diagnostics to Improve Gynecologic Health (R43/R44 - Clinical Trial Optional)
Funding Opportunity RFA-HD-19-006 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to encourage small businesses to collaborate with scientists and clinicians in the field of gynecologic health to develop, advance, and validate new devices and methods for non-invasive diagnosis of endometriosis, adenomyosis, and/or uterine fibroids. Projects supported will aim to shorten the time to diagnosis, decrease the invasiveness of current techniques, and/or improve accessibility, safety, convenience, and costs of diagnosis.
Thu, 14 Dec 2017 03:06:47 EST

Deciphering the Molecular Landscape of Lung Aging in Humans (U01 - Clinical Trial Not Allowed)
Funding Opportunity RFA-HL-19-012 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications to study the normal biological aging process in the human lungs; specifically focusing on a) changes in molecular hallmarks of aging and b) building a dynamic molecular map of aging in the lung that can be used as a reference for researchers to better define the mechanisms of age-related lung diseases.
Thu, 14 Dec 2017 12:39:38 EST

BRAIN Initiative: Targeted BRAIN Circuits Planning Projects TargetedBCPP (R34 - Clinical Trials Not Allowed)
Funding Opportunity RFA-NS-18-014 from the NIH Guide for Grants and Contracts. This R34 FOA solicits applications that offer a limited scope of aims and an approach that will establish feasibility, validity, or other technically qualifying results that, if successful, would support, enable, and/or lay the groundwork for a potential, subsequent Targeted Brain Circuits Projects - TargetedBCP R01, as described in the companion FOA (RFA-NS-18-009). Applications should be exploratory research projects that use innovative, methodologically-integrated approaches to understand how circuit activity gives rise to mental experience and behavior.
Thu, 14 Dec 2017 03:22:53 EST

BRAIN Initiative: Biology and Biophysics of Neural Stimulation (R01 - Clinical Trials Optional)
Funding Opportunity RFA-NS-18-018 from the NIH Guide for Grants and Contracts. A central goal of the BRAIN Initiative is to develop new and improved perturbation technologies suitable for controlling specified cell types and circuits to modulate function in the central nervous system. This FOA seeks applications to systematically characterize, model, and validate the membrane, cellular, circuit, and adaptive-biological responses of neuronal and non-neuronal cells to various types of stimulation. Development of new technologies and therapies, as well as of disease models are outside the scope of this FOA. However, activities related to combining multiple recording modalities are allowed. As part of this program, investigators will be required to participate in a consortium to develop standards and model systems for the evaluation of current and next generation neuromodulation technologies.
Thu, 14 Dec 2017 02:50:58 EST

Studies in Neonatal and Pediatric Resuscitation (R01 Clinical Trial Optional)
Funding Opportunity PA-18-485 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to stimulate research on a wide range of topics related to neonatal and pediatric resuscitation. Possible topics may include, but are not limited to: fetal-neonatal transitional cardiovascular and pulmonary physiology, optimizing steps of resuscitation, management of third stage of labor and its effect on the fetus, resuscitation of children with malformations, effect of resuscitation on long-term outcomes and post-resuscitation practices. Proposals can include epidemiological studies, studies utilizing fetal-neonatal animal models, computer or other information-technology-based simulations or study designs, clinical observational studies, analyses of pre-existing national or regional datasets, opportunistic studies, prospective randomized controlled trials, or any combinations thereof. It is anticipated that the results from well-conducted studies will enable translation of knowledge into evidence-based resuscitation practices ensuring a optimal short- and long-term outcomes for all newborn infants and children.
Mon, 11 Dec 2017 10:36:55 EST

Studies in Neonatal and Pediatric Resuscitation (R03 - Clinical Trial Optional)
Funding Opportunity PA-18-491 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to stimulate research on a wide range of topics related to neonatal and pediatric resuscitation. Possible topics may include, but are not limited to: fetal-neonatal transitional cardiovascular and pulmonary physiology, optimizing steps of resuscitation, management of third stage of labor and its effect on the fetus, resuscitation of children with malformations, effect of resuscitation on long-term outcomes and post-resuscitation practices. Proposals can include epidemiological studies, studies utilizing fetal-neonatal animal models, computer or other information-technology-based simulations or study designs, clinical observational studies, analyses of pre-existing national or regional datasets, opportunistic studies prospective randomized controlled trials, or any combinations thereof. It is anticipated that the results from well-conducted studies will enable translation of knowledge into evidence-based resuscitation practices ensuring a optimal short- and long-term outcomes for all newborn infants and children.
Mon, 11 Dec 2017 10:36:51 EST

Using Information Technology to Support Systematic Screening and Treatment of Depression in Cancer (R21 Clinical Trial Optional)
Funding Opportunity PA-18-492 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) encourages research to understand how information technology (IT) can support systematic screening and treatment of depression in cancer patients in a variety of oncology practice settings. The goals of this FOA are to: identify new, IT-enabled delivery models that support systematic screening and treatment of depression in cancer patients; test the feasibility of implementing these new delivery models in a variety of oncology practice settings, especially those serving under-served populations; and test the effectiveness of these new delivery models, and their components, in a variety of oncology practice settings, especially those serving under-served populations.
Mon, 11 Dec 2017 11:08:51 EST

Using Information Technology to Support Systematic Screening and Treatment of Depression in Cancer (R01 Clinical Trial Optional)
Funding Opportunity PA-18-493 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) encourages research to understand how information technology (IT) can support systematic screening and treatment of depression in cancer patients in a variety of oncology practice settings. The goals of this FOA are to: identify new, IT-enabled delivery models that support systematic screening and treatment of depression in cancer patients; test the feasibility of implementing these new delivery models in a variety of oncology practice settings, especially those serving under-served populations; and test the effectiveness of these new delivery models, and their components, in a variety of oncology practice settings, especially those serving under-served populations.
Mon, 11 Dec 2017 11:09:00 EST

Academic Research Enhancement Award in Diseases within the Mission of NIDDK (R15 - Clinical Trial Required)
Funding Opportunity PA-18-495 from the NIH Guide for Grants and Contracts. The purpose of the Academic Research Enhancement Award (AREA) program is to stimulate research in educational institutions that provide baccalaureate or advanced degrees for a significant number of the Nation's research scientists, but that have not been major recipients of NIH support. AREA grants create opportunities for scientists and institutions otherwise unlikely to participate extensively in NIH research programs to contribute to the Nation's biomedical and behavioral research effort. AREA grants are intended to support small-scale research projects proposed by faculty members of eligible, domestic institutions, to expose undergraduate and/or graduate students to meritorious research projects, and to strengthen the research environment of the applicant institution. The purpose of this FOA is to support AREA grants for clinical trials focused on diseases within the mission of NIDDK.
Mon, 11 Dec 2017 01:14:50 EST

Academic Research Enhancement Award (Parent R15 Clinical Trial Not Allowed)
Funding Opportunity PA-18-504 from the NIH Guide for Grants and Contracts. The purpose of the Academic Research Enhancement Award (AREA) program is to stimulate research in educational institutions that provide baccalaureate or advanced degrees for a significant number of the Nation's research scientists, but that have not been major recipients of NIH support. AREA grants create opportunities for scientists and institutions otherwise unlikely to participate extensively in NIH research programs to contribute to the Nation's biomedical and behavioral research effort. AREA grants are intended to support small-scale research projects proposed by faculty members of eligible, domestic institutions, to expose undergraduate and/or graduate students to meritorious research projects, and to strengthen the research environment of the applicant institution.
Wed, 13 Dec 2017 11:10:17 EST

NIDCD Early Career Research(ECR) Award (R21 - Clinical Trials Optional)
Funding Opportunity PAR-18-487 from the NIH Guide for Grants and Contracts. The NIDCD Early Career Research (ECR) Award (R21) is intended to support both basic and clinical research from scientists who are beginning to establish an independent research career. It cannot be used for thesis or dissertation research. The research must be focused on one or more of the areas within the biomedical and behavioral scientific mission of the NIDCD: hearing, balance, smell, taste, voice, speech, or language. The NIDCD ECR Award R21 grant mechanism supports different types of projects including secondary analysis of existing data; small, self-contained research projects; development of research methodology; translational research; outcomes research; and development of new research technology. Irrespective of the type of project, the intent of the NIDCD ECR Award R21 is for the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) to obtain sufficient preliminary data for a subsequent R01 application.
Mon, 11 Dec 2017 09:47:29 EST